File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008

TitleManagement of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008
Authors
KeywordsAnti-Obesity Drugs
Obesity
Orlistat
Phentermine
Sibutramine
Issue Date2012
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/annepidem
Citation
Annals of Epidemiology, 2012, v. 22 n. 5, p. 349-353 How to Cite?
AbstractPURPOSE: The prevalence of obesity has been increasing in the United States. We set out to investigate the use of pharmacologic and non-pharmacologic therapy for the treatment of obesity in recent years. METHODS: We included 2630 men and 2702 women who took part in the National Health and Nutrition Examination Survey from 2007 to 2008. We analyzed their demographic and anthropometric data and their weight and drug history. RESULTS: A total of 45.9% of men and 45.0% of women were candidates for treatment (body mass index >/=30 kg/m(2), or >/=27 kg/m(2) with risk factors). Among these participants, 85.1% considered themselves overweight, 90.1% would like to lose weight, 61.9% had dietary changes, 36.5% exercised, 3.7% took nonprescription drugs, and 2.2% took prescription drugs to control weight during the preceding year. During the preceding month, 0.5% and 0.1% of participants were taking phentermine and orlistat, respectively. There were no participants on sibutramine. CONCLUSIONS: Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication. The withdrawal of sibutramine would have minimal impact on the general population. There is a need for more lifestyle changes in the majority of obese individuals.
Persistent Identifierhttp://hdl.handle.net/10722/163481
ISSN
2021 Impact Factor: 6.996
2020 SCImago Journal Rankings: 1.644
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSamaranayake, NRen_US
dc.contributor.authorOng, KLen_US
dc.contributor.authorLeung, RYHen_US
dc.contributor.authorCheung, BMYen_US
dc.date.accessioned2012-09-05T05:31:50Z-
dc.date.available2012-09-05T05:31:50Z-
dc.date.issued2012en_US
dc.identifier.citationAnnals of Epidemiology, 2012, v. 22 n. 5, p. 349-353en_US
dc.identifier.issn1047-2797en_US
dc.identifier.urihttp://hdl.handle.net/10722/163481-
dc.description.abstractPURPOSE: The prevalence of obesity has been increasing in the United States. We set out to investigate the use of pharmacologic and non-pharmacologic therapy for the treatment of obesity in recent years. METHODS: We included 2630 men and 2702 women who took part in the National Health and Nutrition Examination Survey from 2007 to 2008. We analyzed their demographic and anthropometric data and their weight and drug history. RESULTS: A total of 45.9% of men and 45.0% of women were candidates for treatment (body mass index >/=30 kg/m(2), or >/=27 kg/m(2) with risk factors). Among these participants, 85.1% considered themselves overweight, 90.1% would like to lose weight, 61.9% had dietary changes, 36.5% exercised, 3.7% took nonprescription drugs, and 2.2% took prescription drugs to control weight during the preceding year. During the preceding month, 0.5% and 0.1% of participants were taking phentermine and orlistat, respectively. There were no participants on sibutramine. CONCLUSIONS: Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication. The withdrawal of sibutramine would have minimal impact on the general population. There is a need for more lifestyle changes in the majority of obese individuals.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/annepidemen_US
dc.relation.ispartofAnnals of Epidemiologyen_US
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Annals of Epidemiology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Annals of Epidemiology, 2012, v. 22 n. 5, p. 349-353. DOI: 10.1016/j.annepidem.2012.01.001-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAnti-Obesity Drugs-
dc.subjectObesity-
dc.subjectOrlistat-
dc.subjectPhentermine-
dc.subjectSibutramine-
dc.subject.meshAnti-Obesity Agents - therapeutic use-
dc.subject.meshCyclobutanes - therapeutic use-
dc.subject.meshExercise-
dc.subject.meshNutrition Surveys-
dc.subject.meshObesity - epidemiology - therapy-
dc.titleManagement of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008en_US
dc.typeArticleen_US
dc.identifier.emailLeung, RYH: yhleung@hkucc.hku.hken_US
dc.identifier.emailCheung, BMY: mycheung@hku.hk-
dc.identifier.authorityCheung, BMY=rp01321en_US
dc.description.naturepostprinten_US
dc.identifier.doi10.1016/j.annepidem.2012.01.001en_US
dc.identifier.pmid22305325-
dc.identifier.scopuseid_2-s2.0-84860246159en_US
dc.identifier.hkuros204052-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84860246159&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume22en_US
dc.identifier.issue5en_US
dc.identifier.spage349en_US
dc.identifier.epage353en_US
dc.identifier.isiWOS:000303783900006-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridCheung, BMY=7103294806en_US
dc.identifier.scopusauthoridLeung, RYH=7101876102en_US
dc.identifier.scopusauthoridOng, KL=8340854000en_US
dc.identifier.scopusauthoridSamaranayake, NR=37081701500en_US
dc.identifier.citeulike10318482-
dc.identifier.issnl1047-2797-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats